phase

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – December 14,…

3 weeks ago

Mutuum Finance (MUTM) Completes Smart Contracts in Preparation for Q4 2025 Testing

Dubai, UAE, Dec. 14, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM), a decentralized finance (DeFi) project focused on lending and…

3 weeks ago

New Crypto Coin Mutuum Finance (MUTM) Nears 100% of Phase 6 Allocation as Investor Activity Accelerates

Dubai, UAE, Dec. 13, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM), a new crypto coin positioned in the decentralized finance…

4 weeks ago

Milano Cortina 2026 organisers highlight Games readiness and momentum in update to the IOC Executive Board

10 December 2025 - As anticipation builds across Italy and beyond, the Milano Cortina 2026 Organising Committee briefed the International Olympic Committee’s (IOC)’s…

4 weeks ago

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…

4 weeks ago

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed…

4 weeks ago

TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

December 06, 2025 17:30 ET  | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…

1 month ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

1 month ago

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease

December 05, 2025 21:00 ET  | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…

1 month ago

GENESIS MOTOR EUROPE ANNOUNCES MAXIMILIAN KALBFELL AS NEW HEAD OF MARKETING

Genesis Motor Europe strengthens its executive team, with the appointment of Maximilian KalbfellBringing over 20 years of marketing experience, Maximilian…

1 month ago